Pharmacy News

Forxiga has had a string of successes recently, as it was recommended by NICE and had its EU marketing authorisation updated earlier this month.

The drive includes a one-hour identification and treatment ambition, as well as a new ‘alert and action’ technology.

Alzheimer's is a complex disease with lots of failed treatments in past pipelines.

The UK has lost its ‘measles-free’ status with WHO, just three years after the virus was eliminated in the country.

Researchers found that the test was able to identify circulating tumour DNA in every patient before they started treatment.

Swingeing cuts in social care that have left around 1.4 million older people in England unable to access the care and support they need.

In the SELECT programme, the oral JAK inhibitor met all primary and ranked secondary endpoints across a variety of rheumatoid arthritis patients.

For the indication of ROS1-positive, metastatic non-small cell lung cancer (NSCLC).

UK Meds has announced a partnership with Onfido to make buying prescription-only medicines online much safer.

CONFIRM is the largest-ever prospective study conducted in patients with hepatorenal syndrome type I.

The Health and Social Care Secretary has announced an evidence-based review into the service.

The NHS estimates there could be 2,500 fewer emergency admissions to hospital a year for patients with progressive neurological conditions.

The new project could ‘help surgeons to visualise tumours during keyhole surgery’.

The £25 million contract to set up an express freight service aims to be completed in the next one to four days.

On average patients entered the trial with LDL cholesterol levels of 255 mg/dL, despite treatment with other lipid-lowering therapies.

The drug met the primary and all major secondary endpoints up to week 12 in the Phase IV IXORA-R study.

Now in its 26th year, this prestigious competition has a long history of discovering and rewarding the very best healthcare marketers and last year was no exception.

Two new drugs, mAb114 and REGN-EB3, have been found to dramatically cut mortality from Ebola.

The drug has been approved for chronic lymphocytic leukaemia.

The approval follows the Positive Opinion from the European Medicines Agency’s CHMP, and marks the fifth European approval in as many years.